1. Search Result
Search Result
Results for "

renal anemia

" in MedChemExpress (MCE) Product Catalog:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-131346

    HIF/HIF Prolyl-Hydroxylase Cardiovascular Disease
    HIF-PHD-IN-1 is an orally active inhibitor of hypoxia-inducible factor prolyl hydroxylase domain (HIF-PHD), with an IC50 of 54 nM for hHIF-PHD2. HIF-PHD-IN-1 is promising therapeutic agents for renal anemia .
    HIF-PHD-IN-1
  • HY-147025

    PROTACs TGF-beta/Smad HIF/HIF Prolyl-Hydroxylase Inflammation/Immunology Cancer
    (S,R,S)-AHPC-C2-amide-benzofuranylmethyl-pyridine is a dual target PROTAC that can not only target to the ubiquitination and degradation of Smad3 but also improve the HIF-α protein level. (S,R,S)-AHPC-C2-amide-benzofuranylmethyl-pyridine has a multi-path anti-fibrosis function and a renal protection function for research of renal anemia. (S,R,S)-AHPC-C2-amide-benzofuranylmethyl-pyridine can be used for research on prostate cancer and other cancers .
    (S,R,S)-AHPC-C2-amide-benzofuranylmethyl-pyridine
  • HY-12654
    Molidustat
    Maximum Cited Publications
    6 Publications Verification

    BAY 85-3934

    HIF/HIF Prolyl-Hydroxylase Cardiovascular Disease
    Molidustat (BAY 85-3934) is an orally active inhibitor of hypoxia-inducible factor prolyl hydroxylase (HIF-PH) with IC50 values of 480 nM, 280 nM, and 450 nM for PHD1, PHD2, and PHD3, respectively. Molidustat can elevate the levels of circulating erythropoietin (EPO) to near-normal physiological ranges. Molidustat can be utilized in the research of renal anemia .
    Molidustat
  • HY-109057
    Enarodustat
    4 Publications Verification

    JTZ-951; SAL0951

    HIF/HIF Prolyl-Hydroxylase Metabolic Disease
    Enarodustat is a potent and orally active hypoxia-inducible factor prolyl hydroxylase inhibitor, with an EC50 of 0.22 μM. Enarodustat has the potential for renal anemia treatment.
    Enarodustat
  • HY-139855

    HIF/HIF Prolyl-Hydroxylase Metabolic Disease
    ZG-2033 (Compound 26) is an orally active HIF-2α agonist that demonstrates nanomolar activity in luciferase reporter gene assays (EC50 = 490 nM). ZG-2033 has the effect of alleviating anemia and exhibits synergistic action with AKB-6548 (HY-101277) in anemia, and can be used in the study of renal anemia .
    ZG-2033
  • HY-161660

    HIF/HIF Prolyl-Hydroxylase Cardiovascular Disease Metabolic Disease
    DS44470011 is a hypoxia-inducing factor prolyl hydroxylase (HIF-PHD) inhibitor. DS44470011 has oral activity. DS44470011 promotes cell release of erythropoietin (EPO). DS44470011 can be used in the research of renal anemia .
    DS44470011
  • HY-W747868

    HIF/HIF Prolyl-Hydroxylase Cardiovascular Disease
    Molidustat sodium is an orally active inhibitor of hypoxia-inducible factor prolyl hydroxylase (HIF-PH) with IC50 values of 480 nM, 280 nM, and 450 nM for PHD1, PHD2, and PHD3, respectively. Molidustat sodium can elevate the levels of circulating erythropoietin (EPO) to near-normal physiological ranges. Molidustat sodium can be utilized in the research of renal anemia .
    Molidustat sodium
  • HY-12654R

    HIF/HIF Prolyl-Hydroxylase Cardiovascular Disease
    Molidustat (Standard) is the analytical standard of Molidustat. This product is intended for research and analytical applications. Molidustat (BAY 85-3934) is an orally active inhibitor of hypoxia-inducible factor prolyl hydroxylase (HIF-PH) with IC50 values of 480 nM, 280 nM, and 450 nM for PHD1, PHD2, and PHD3, respectively. Molidustat can elevate the levels of circulating erythropoietin (EPO) to near-normal physiological ranges. Molidustat can be utilized in the research of renal anemia .
    Molidustat (Standard)
  • HY-109057A

    JTZ-951 hydrochloride; SAL0951 hydrochloride

    HIF/HIF Prolyl-Hydroxylase Metabolic Disease
    Enarodustat hydrochloride is a potent and orally active HIF/HIF Prolyl-Hydroxylase inhibitor, with an EC50 of 0.22 μM. Enarodustat hydrochloride has the potential for renal anemia treatment.
    Enarodustat hydrochloride
  • HY-176408

    HIF/HIF Prolyl-Hydroxylase Cardiovascular Disease
    PHD2-IN-5 (compound 22) is a potent PHD2 inhibitor with an IC50 of 0.82 μM. PHD2-IN-5 can be used in the study of renal anemia .
    PHD2-IN-5
  • HY-163839

    HIF/HIF Prolyl-Hydroxylase Metabolic Disease
    DS-1093a is an orally active hypoxia-inducible factor prolyl hydroxylase (HIF-PHD) inhibitor, with an EC50 of 0.49 μM in Hep3B cell EPO production. DS-1093a can be used in the research of renal anemia .
    DS-1093a
  • HY-161265

    HIF/HIF Prolyl-Hydroxylase Metabolic Disease
    HIF-2α agonist 3 (Compound 14d) is an orally active HIF-2α agonist with a EC50 value of 1.78 μM. HIF-2α agonist 3 can be used in the study of renal anemia .
    HIF-2α agonist 3
  • HY-112144
    TP0463518
    1 Publications Verification

    HIF/HIF Prolyl-Hydroxylase Metabolic Disease Inflammation/Immunology
    TP0463518 is an orally active, competitive pan-inhibitor of hypoxia-inducible factor prolyl hydroxylases PHD1/2/3. TP0463518 competitively inhibits human PHD1 (IC50=18 nM), PHD2 (Ki=5.3 nM), and PHD3 (IC50=63 nM), and targets monkey PHD2 with an IC50 of 22 nM. TP0463518 inhibits PHD-catalyzed hydroxylation to stabilize HIFα, thereby upregulating erythropoietin (EPO) expression and enhancing intestinal iron absorption (such as increased DMT-1 and dCYTb expression), improving anemia. TP0463518 is mainly used for the research of renal anemia and inflammatory anemia .
    TP0463518

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: